Showing results (61-70 of 264) with videos related to

Sort By:
Pageof 27
Neurology|February 20, 2025
Clinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post-hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study (P4-11.001)Ali A Habib, Henry J Kaminski, Julian Grosskreutz, et al.
Pediatric Research|November 23, 2017
Pilot study of novel lab methodology and testing of platelet function in adolescent women with heavy menstrual bleedingAnne D Rocheleau, Ayesha Khader, Anh T P Ngo, et al.
VASA. Zeitschrift Fur Gefasskrankheiten|August 23, 2014
G-protein coupled receptor auto-antibodies in thromboangiitis obliterans (Buerger's disease) and their removal by immunoadsorptionPeter F Klein-Weigel, Marion Bimmler, Petra Hempel, et al.
The British Journal of Dermatology|July 12, 2020
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)K B Gordon, R B Warren, A B Gottlieb, et al.
The British Journal of Dermatology|June 13, 2020
Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studiesA Blauvelt, C Paul, P van de Kerkhof, et al.
Fertility and Sterility|July 7, 2015
Antimüllerian hormone as a predictor of good-quality supernumerary blastocyst cryopreservation among women with levels <1 ng/mL versus 1-4 ng/mLShahryar K Kavoussi, Kate C Odenwald, Lynn M Boehnlein, et al.
Journal of Neuromuscular Diseases|March 4, 2025
Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensionsVera Bril, Artur Drużdż, Julian Grosskreutz, et al.
Journal of Neurology|October 11, 2025
Self-administration of rozanolixizumab via manual push and infusion pump methods in patients with generalised myasthenia gravis: a randomised, phase 3, open-label, crossover studyVera Bril, Carlo Antozzi, Tomasz Berkowicz, et al.
Journal of Neurology|March 19, 2025
Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 studyVera Bril, Artur Drużdż, Julian Grosskreutz, et al.
Therapeutic Advances in Neurological Disorders|July 2, 2026
Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensionsVera Bril, Artur Drużdż, Julian Grosskreutz, et al.
Pageof 27